ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

orevandrodeg

Its studies are mostly in Prostatic Neoplasms, led by Bristol-Myers Squibb.

Furthest: phase 1, since Sep 28, 20232 company-led studies, 1 open or runningNext primary completion: Aug 24, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb21 open or runningphase 1since Sep 28, 2023Sep 28, 2023Aug 24, 2029phase 1 · NCT06067841
  • Named in Bristol-Myers Squibb’s own pipeline as BMS-986460, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2023First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06067841 · 140 planned · United States, Canada, France
  2. Mar 10, 2025Phase 1 study in Healthy VolunteersNCT06877702 · 85 enrolled · United States
  3. Jan 29, 2026Named orevandrodegINNProposed as its International Nonproprietary Name in WHO's List 134 · before, BMS-986460

Ahead

  1. Aug 24, 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT06067841

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06877702Healthy Volunteers · United States1CompletedDec 17, 202585
NCT06067841Prostatic Neoplasms · United States, Canada, France1RecruitingAug 24, 2029140

How it is read

Names in the registry

  • “BMS-986460”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.